Home / Market News / $JANX

$JANX news and market catalysts

The 11 most recent market catalysts affecting $JANX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

11 catalysts 2 high impact 5 bullish 2 bearish Biotechnology
Nov 13, 2026 Corporate Catalyst Bearish Impact 65
Wolfe Research Downgrades Janux Therapeutics to Hold
Wolfe Research analyst Kalpit Patel downgraded Janux Therapeutics (JANX) to a 'Hold' rating on November 12, 2026. This action signifies a more cautious stance from a prominent rese…
Nov 11, 2026 Corporate Catalyst Neutral Impact 55
UBS Initiates Coverage of Janux Therapeutics with Hold Rating
UBS analyst David Dai initiated coverage of Janux Therapeutics (JANX) with a 'Hold' rating and a $15 price target. This event is significant as it marks the formal entry of a major…
Nov 9, 2026 Corporate Catalyst Bullish Impact 85
Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011
Janux Therapeutics announced positive initial Phase 1 clinical trial results for JANX011, its lead candidate from the ARM platform. The data showed deep, sustained B-cell depletion…
Nov 6, 2026 Corporate Catalyst Neutral Impact 55
Barclays and Wedbush Update Price Targets for Janux Therapeutics
This filing discloses that two prominent investment banks, Barclays and Wedbush, have updated their price targets for Janux Therapeutics (JANX) after the company's Q3 earnings repo…
Nov 6, 2026 Corporate Catalyst Bullish Impact 65
Wedbush Raises Price Target on Janux Therapeutics to $40
Wedbush Securities has raised its price target for Janux Therapeutics to $40, up from $36, and maintained its 'Outperform' rating. This positive analyst action is a direct response…
Nov 5, 2026 Corporate Catalyst Neutral Impact 75
Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Janux Therapeutics reported its third-quarter 2026 financial results and, more importantly for a clinical-stage biotech, provided an update on its clinical pipeline. The key develo…
Nov 2, 2026 Corporate Catalyst Neutral Impact 65
Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011
Janux Therapeutics is holding a virtual event to present initial Phase 1 clinical data for JANX011, an immunotherapy candidate. This event is significant because it will be the fir…
Aug 24, 2026 Corporate Catalyst Bullish Impact 75
Janux Therapeutics shares are trading higher after Wolfe Research upgraded the stock from Peer Perform to Outperform rating and announced a $23 price target.
This headline indicates a strong positive catalyst for Janux Therapeutics. Analyst upgrades, especially from 'Peer Perform' to 'Outperform' with a specific price target, often act …
Aug 24, 2026 Corporate Catalyst Bullish Impact 65
Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target
Wolfe Research analyst Kalpit Patel upgraded Janux Therapeutics (JANX) from 'Peer Perform' to 'Outperform' and announced a new price target of $23. This upgrade indicates a more po…
Aug 7, 2026 Corporate Catalyst Bearish Impact 55
Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55
Guggenheim analyst Brad Canino maintained a 'Buy' rating on Janux Therapeutics but adjusted the price target downwards from $58 to $55. This action signals that while the analyst s…
Aug 6, 2026 Corporate Catalyst Bullish Impact 92
Janux Therapeutics Q2 EPS $(0.35) Beats $(0.38) Estimate, Sales $10.267M Miss $16.493M Estimate
Janux Therapeutics' Q2 earnings report presents a mixed picture. While the company successfully narrowed its losses per share, beating analyst expectations, the substantial miss on…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.